HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with a primary focus in oncology and hematology, announced today the launch of the Company’s new patient campaign for ZEVALIN (ibritumomab tiuxetan) Injection for Intravenous Use, on ZEVALIN.com.
